Literature DB >> 11854651

Maternal serum activin A, inhibin A, and follistatin in pregnancies with appropriately grown and small-for-gestational-age fetuses classified by umbilical artery Doppler ultrasound.

Catherine S Bobrow1, Robert P Holmes, Shanthi Muttukrishna, Ajitha Mohan, Nigel Groome, Deirdre J Murphy, Peter W Soothill.   

Abstract

OBJECTIVE: The purpose of this study was to examine the relationship of maternal serum activin A, inhibin A, and follistatin with fetal growth and placental function. STUDY
DESIGN: Inhibin A, activin A, and follistatin were measured in maternal serum that was stored from normally grown (control subjects, n = 50) and small-for-gestational-age pregnancies (n = 49), prospectively classified as normal small-for-gestational-age pregnancy or fetal growth-restricted pregnancy with the use of umbilical artery Doppler ultrasound.
RESULTS: Activin A and inhibin A were significantly increased in fetal growth-restricted pregnancies compared with control subjects (activin A: regression coefficient, 0.54, P <.001; inhibin A: regression coefficient, 0.47, P =.003). The activin:follistatin ratio was significantly higher in fetal growth-restricted pregnancies compared with control subjects (P <.001). There were no significant differences between analyte levels of normal small-for-gestational-age pregnancies and control subjects.
CONCLUSION: Maternal serum activin A, inhibin A, and activin:follistatin ratio are raised in fetal growth-restricted pregnancies but not in normal small-for-gestational age pregnancies. This provides further evidence of the difference between subgroups within small-for-gestational-age pregnancies and emphasizes the need to stratify for this in research.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854651     DOI: 10.1067/mob.2002.119777

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

Review 1.  Management of fetal growth restriction.

Authors:  M Alberry; P Soothill
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-01       Impact factor: 5.747

2.  Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study from the Walker cohort.

Authors:  G Libby; D J Murphy; N F McEwan; S A Greene; J S Forsyth; P W Chien; A D Morris
Journal:  Diabetologia       Date:  2006-12-23       Impact factor: 10.122

3.  Expression of inhibin/activin subunits alpha (-alpha), beta A (-beta (A)) and beta B (-beta (B)) in placental tissue of normal and intrauterine growth restricted (IUGR) pregnancies.

Authors:  I Mylonas; B Schiessl; U Jeschke; J Vogl; A Makrigiannakis; C Kuhn; S Kunze; S Schulze; F Kainer; K Friese
Journal:  J Mol Histol       Date:  2006-05-03       Impact factor: 2.611

4.  Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants.

Authors:  Alexander Ep Heazell; Dexter Jl Hayes; Melissa Whitworth; Yemisi Takwoingi; Susan E Bayliss; Clare Davenport
Journal:  Cochrane Database Syst Rev       Date:  2019-05-14

5.  Serum activin A and follistatin levels in gestational diabetes and the association of the Activin A-Follistatin system with anthropometric parameters in offspring.

Authors:  Silvia Näf; Xavier Escote; Mónica Ballesteros; Rosa Elena Yañez; Inmaculada Simón-Muela; Pilar Gil; Gerard Albaiges; Joan Vendrell; Ana Megia
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

6.  The prediction of early preeclampsia: Results from a longitudinal proteomics study.

Authors:  Adi L Tarca; Roberto Romero; Neta Benshalom-Tirosh; Nandor Gabor Than; Dereje W Gudicha; Bogdan Done; Percy Pacora; Tinnakorn Chaiworapongsa; Bogdan Panaitescu; Dan Tirosh; Nardhy Gomez-Lopez; Sorin Draghici; Sonia S Hassan; Offer Erez
Journal:  PLoS One       Date:  2019-06-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.